AAAAAA

   
Results: 1-11 |
Results: 11
IRINOTECAN IN THE FIRST-LINE TREATMENT OF COLORECTAL-CANCER
Authors: SALTZ LB
Citation: Lb. Saltz, IRINOTECAN IN THE FIRST-LINE TREATMENT OF COLORECTAL-CANCER, Oncology, 12(8), 1998, pp. 54-58
IRINOTECAN AND CISPLATIN IN UPPER GASTROINTESTINAL MALIGNANCIES
Authors: ENZINGER PC ILSON DH SALTZ LB OREILLY EM KELSEN DP
Citation: Pc. Enzinger et al., IRINOTECAN AND CISPLATIN IN UPPER GASTROINTESTINAL MALIGNANCIES, Oncology, 12(8), 1998, pp. 110-113
A PHASE-II STUDY OF TOPOTECAN ADMINISTERED 5 TIMES DAILY IN PATIENTS WITH ADVANCED GASTRIC-CANCER
Authors: SALTZ LB SCHWARTZ GK ILSON DH QUAN V KELSEN DP
Citation: Lb. Saltz et al., A PHASE-II STUDY OF TOPOTECAN ADMINISTERED 5 TIMES DAILY IN PATIENTS WITH ADVANCED GASTRIC-CANCER, American journal of clinical oncology, 20(6), 1997, pp. 621-625
ADJUVANT TREATMENT OF COLORECTAL-CANCER
Authors: SALTZ LB KELSEN DP
Citation: Lb. Saltz et Dp. Kelsen, ADJUVANT TREATMENT OF COLORECTAL-CANCER, Annual review of medicine, 48, 1997, pp. 191-202
9-AMINOCAMPTOTHECIN BY 72-HOUR CONTINUOUS INTRAVENOUS-INFUSION IS INACTIVE IN THE TREATMENT OF PATIENTS WITH 5-FLUOROURACIL-REFRACTORY COLORECTAL-CARCINOMA
Authors: SALTZ LB KEMENY NE TONG W HARRISON J BERKERY R KELSEN DP
Citation: Lb. Saltz et al., 9-AMINOCAMPTOTHECIN BY 72-HOUR CONTINUOUS INTRAVENOUS-INFUSION IS INACTIVE IN THE TREATMENT OF PATIENTS WITH 5-FLUOROURACIL-REFRACTORY COLORECTAL-CARCINOMA, Cancer, 80(9), 1997, pp. 1727-1732
INFLUENCE OF INFLAMMATORY BOWEL-DISEASE ON THE ABILITY OF PATIENTS TOTOLERATE SYSTEMIC FLUOROURACIL-BASED CHEMOTHERAPY
Authors: TIERSTEN A SALTZ LB
Citation: A. Tiersten et Lb. Saltz, INFLUENCE OF INFLAMMATORY BOWEL-DISEASE ON THE ABILITY OF PATIENTS TOTOLERATE SYSTEMIC FLUOROURACIL-BASED CHEMOTHERAPY, Journal of clinical oncology, 14(7), 1996, pp. 2043-2046
IRINOTECAN IS AN ACTIVE AGENT IN UNTREATED PATIENTS WITH METASTATIC COLORECTAL-CANCER
Authors: CONTI JA KEMENY NE SALTZ LB HUANG Y TONG WP CHOU TC SUN M PULLIAM S GONZALEZ C
Citation: Ja. Conti et al., IRINOTECAN IS AN ACTIVE AGENT IN UNTREATED PATIENTS WITH METASTATIC COLORECTAL-CANCER, Journal of clinical oncology, 14(3), 1996, pp. 709-715
PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF IRINOTECAN, FLUOROURACIL, ANTI LEUCOVORIN IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: SALTZ LB KANOWITZ J KEMENY NE SCHAAF L SPRIGGS D STATON BA BERKERY R STEGER C ENG M DIETZ A LOCKER P KELSEN DP
Citation: Lb. Saltz et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF IRINOTECAN, FLUOROURACIL, ANTI LEUCOVORIN IN PATIENTS WITH ADVANCED SOLID TUMORS, Journal of clinical oncology, 14(11), 1996, pp. 2959-2967
ACUTE HYPERTENSIVE CRISIS FOLLOWING OCTREOTIDE ADMINISTRATION IN A PATIENT WITH MALIGNANT PHEOCHROMOCYTOMA
Authors: SALTZ LB TIERSTEN A HASSAN BN GROEGER JS
Citation: Lb. Saltz et al., ACUTE HYPERTENSIVE CRISIS FOLLOWING OCTREOTIDE ADMINISTRATION IN A PATIENT WITH MALIGNANT PHEOCHROMOCYTOMA, Oncology Reports, 2(6), 1995, pp. 1129-1130
CONTINUOUS-INFUSION FLUOROURACIL LEUCOVORIN AND BOLUS MITOMYCIN-C AS A SALVAGE REGIMEN FOR PATIENTS WITH ADVANCED COLORECTAL-CANCER
Authors: CONTI JA KEMENY NE SALTZ LB ANDRE AM GROSSANO DD BERTINO JR
Citation: Ja. Conti et al., CONTINUOUS-INFUSION FLUOROURACIL LEUCOVORIN AND BOLUS MITOMYCIN-C AS A SALVAGE REGIMEN FOR PATIENTS WITH ADVANCED COLORECTAL-CANCER, Cancer, 75(3), 1995, pp. 769-774
A FIXED-RATIO COMBINATION OF URACIL AND FTORAFUR (UFT) WITH LOW-DOSE LEUCOVORIN - AN ACTIVE ORAL REGIMEN FOR ADVANCED COLORECTAL-CANCER
Authors: SALTZ LB LEICHMAN CG YOUNG CW MUGGIA FM CONTI JA SPIESS T JEFFERS S LEICHMAN LP
Citation: Lb. Saltz et al., A FIXED-RATIO COMBINATION OF URACIL AND FTORAFUR (UFT) WITH LOW-DOSE LEUCOVORIN - AN ACTIVE ORAL REGIMEN FOR ADVANCED COLORECTAL-CANCER, Cancer, 75(3), 1995, pp. 782-785
Risultati: 1-11 |